Alnylam Q3 2026 earnings beat, expands nucresiran trial and reaffirms FY‑26 outlook
+1 new source since this summary was written
Alnylam Pharmaceuticals reported third‑quarter 2026 revenue of $1.46 billion, up 17% year‑over‑year, and GAAP net income of $2.2 billion. AMVUTTRA sales rose 65% to $1.13 billion, driving a 59% increase in TTR franchise revenue. Management expanded the Phase 3 TRITON‑CM nucresiran enrollment to about 2,250 patients and reaffirmed its full‑year 2026 guidance, but shares fell roughly 17%‑19% after the release.
Why it matters
The company’s reaffirmed FY‑26 product‑revenue guidance of $4.2‑$4.5 billion (the low end of the range) sets expectations for TTR sales growth and may pressure the stock, as noted by the market reaction (share decline of ~17%‑19%). (source 10) The expanded nucresiran trial signals continued investment in the pipeline, but also adds execution risk that analysts highlight (source 9).
Key facts
- 1Total revenue was $1.46 billion, a 17% increase year over year. fool.com
- 2GAAP net income was $2.2 billion, including a $1.9 billion non‑cash tax benefit. fool.com
- 3AMVUTTRA sales were $1.13 billion, up 65% year over year. fool.com
- 4TTR franchise revenue was $1.15 billion, a 59% increase year over year. fool.com
- 5Full‑year 2026 TTR product‑sales guidance was $4.2 billion to $4.5 billion. fool.com
- 6FY‑26 product‑revenue guidance was $4.7 billion to $5.1 billion. rttnews.com
Open questions
- Full‑year 2026 product‑revenue guidance ranges differ: $4.2‑$4.5 billion for TTR sales (source 10) versus $4.7‑$5.1 billion for total product revenue (source 7).
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.